Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the | Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the biotech, although the U.K. marketing watchdog overturned its severest criticism on appeal.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…
The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. | The LinkedIn…
Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers continue…
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
